Results 11 to 20 of about 4,877,549 (387)

FIGO staging of endometrial cancer: 2023

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023
Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009.
Jonathan S Berek, X. Matías-Guiu, C. Creutzberg, C. Fotopoulou, D. Gaffney, S. Kehoe, K. Lindemann, D. Mutch, N. Concin   +8 more
semanticscholar   +2 more sources

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

New England Journal of Medicine, 2022
BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previously ...
V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. Guerra, U. Şanlı, M. McCormack, Alan Smith, S. Keefe, Steven Bird, L. Dutta, R. Orlowski, D. Lorusso   +23 more
semanticscholar   +1 more source

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer.
M. Mirza, D. Chase, B. Slomovitz, René dePont Christensen, Z. Novak, D. Black, L. Gilbert, Sudarshan Sharma, G. Valabrega, L. Landrum, L. Hanker, A. Stuckey, I. Boere, M. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. Shahin, S. Gill, B. Monk, J. Buscema, T. Herzog, L. Copeland, Min Tian, Zangdong He, S. Stevens, E. Zografos, R. Coleman, M. Powell   +30 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

New England Journal of Medicine, 2023
BACKGROUND Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.
R. Eskander, M. Sill, L. Beffa, Richard G. Moore, J. Hope, Fernanda B. Musa, R. Mannel, M. Shahin, G. Cantuaria, E. Girda, C. Mathews, J. Kavecansky, Charles A Leath Iii, L. Gien, E. Hinchcliff, S. Lele, L. Landrum, F. Backes, R. O'Cearbhaill, T. Al baghdadi, E. Hill, P. Thaker, V. John, S. Welch, A. Fader, M. Powell, C. Aghajanian   +26 more
semanticscholar   +1 more source

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Journal of Clinical Oncology, 2022
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label ...
D. O’Malley, G. Bariani, P. Cassier, A. Marabelle, A. Hansen, A. de Jesus Acosta, W. Miller, T. Safra, A. Italiano, L. Mileshkin, Lei Xu, F. Jin, K. Norwood, M. Maio   +13 more
semanticscholar   +1 more source

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition

npj Precision Oncology, 2023
Endometrial cancer (EC) patients with metastatic/recurrent disease have limited treatment options and poor survival outcomes. Recently, we discovered the FGFR2c splice isoform is associated with poor prognosis in EC patients.
Asmerom T. Sengal, Vanessa Bonazzi, Deborah Smith, Cristian P. Moiola, Rohan Lourie, Rebecca Rogers, Eva Colas, Antonio Gil-Moreno, Sophia Frentzas, Naven Chetty, Lewis Perrin, Pamela M. Pollock   +11 more
doaj   +1 more source

Multi-trait genome-wide association study identifies a novel endometrial cancer risk locus that associates with testosterone levels

iScience, 2023
Summary: To detect novel endometrial cancer risk variants, we leveraged information from endometrial cancer risk factors in a multi-trait GWAS analysis.
Xuemin Wang, Pik Fang Kho, Dhanya Ramachandran, Cemsel Bafligil, Frederic Amant, Ellen L. Goode, Rodney J. Scott, Ian Tomlinson, D. Gareth Evans, Emma J. Crosbie, Thilo Dörk, Amanda B. Spurdle, Dylan M. Glubb, Tracy A. O'Mara   +13 more
doaj   +1 more source

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023
When determining adjuvant treatment for endometrial cancer, the decision typically relies on factors such as cancer stage, histologic grade, subtype, and a few histopathologic markers.
Ye Yang, Sufang Wu, W. Bao
semanticscholar   +1 more source

Clinicopathological and ultrasound features of endometrial cancer in postmenopausal women: a retrospective study in a single institute in South Korea

The Pan African Medical Journal, 2021
INTRODUCTION: Endometrial cancer is the most common type of cancer in the female genital tract. Most patients are diagnosed during postmenopausal periods. To investigate the demographic characteristics as well as cutoff value of endometrial thickness and
Hyen Chul Jo, Jong Chul Baek, Seon Mi Lee, Ji Eun Park, In Ae Cho, Joo Hyun Sung   +5 more
doaj   +1 more source

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin [PDF]

, 2020
High expression of Ki67, a proliferation marker, is associated with reduced endometrial cancer-specific survival. Pre-surgical metformin reduces tumour Ki-67 expression in some women with endometrial cancer. Metformin's anti-cancer activity may relate to
Crosbie, EJ, Finegan, KG, Kitson, S, Latif, A, Lisanti, MP, Marshall, K, McVey, R, Sivalingam, VN, Sotgia, F, Stratford, IJ   +9 more
core   +2 more sources